title: [Efficacy of anticancer agent-lipiodol emulsion for hepatic arterial infusion and regional hyperthermia in patients with nonresectable hepatoma].
abstract: The efficacy of combination therapy of anticancer agent-Lipiodol Emulsion for hepatic arterial infusion and regional hyperthermia was studied in 102 patients with nonresectable hepatoma. 5-FU, MFA, CDDP and MFA-CDDP were used as anticancer agents in 13, 44, 26 and 19 patients, respectively. One year survival rates of the each group were 9% (1/13, 5-FU-treated), 29% (12/44, MFA-treated), 43% (11/26, CDDP-treated) and 55% (10/19, MFA-CDDP-treated). Tumor regression was found in one out of 11 (9.1%), 11 out 41 (26.8%), 6 out of 23 (26.1) and 9 out of 19 patients (47.4%), respectively. The regional hyperthermia was particularly efficacious for patients with advanced hepatoma (E3 and E4) and clinical stage II, III; 5 out of 32 patients (16%) receiving arterial infusion and hyperthermia survived more than 1 year while all 15 patients without hyperthermia died within 11 months (p less than 0.01). Our data indicate that repeated arterial infusion of MFA and CDDP Lipiodol Emulsion was most effective for nonresectable liver cell cancer, and the regional hyperthermia prolonged the survival of patients who had advanced hepatoma with poor liver function.
authors.affiliation: First Dept. of Surgery, Medical College of Oita.
authors.forename: K
authors.initials: K
authors.lastname: Nakashima
authors.forename: K
authors.initials: K
authors.lastname: Okada
authors.forename: Y
authors.initials: Y
authors.lastname: Iwao
authors.forename: I
authors.initials: I
authors.lastname: Tada
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Aramaki
authors.forename: Y I
authors.initials: YI
authors.lastname: Kim
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: K
authors.initials: K
authors.lastname: Mori
authors.forename: M
authors.initials: M
authors.lastname: Takeyama
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000628:therapy*; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011379:Prognosis
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D007459:Iodized Oil; D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil